Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Development of a Stable MGAT1- CHO Cell Line to Produce Clade C gp120 With Improved Binding to Broadly Neutralizing Antibodies.

Doran RC, Yu B, Wright M, O'Rourke SM, Yin L, Richardson JM, Byrne G, Mesa KA, Berman PW.

Front Immunol. 2018 Oct 5;9:2313. doi: 10.3389/fimmu.2018.02313. eCollection 2018.

2.

CRISPR/Cas9 gene editing for the creation of an MGAT1-deficient CHO cell line to control HIV-1 vaccine glycosylation.

Byrne G, O'Rourke SM, Alexander DL, Yu B, Doran RC, Wright M, Chen Q, Azadi P, Berman PW.

PLoS Biol. 2018 Aug 29;16(8):e2005817. doi: 10.1371/journal.pbio.2005817. eCollection 2018 Aug.

3.

Robotic selection for the rapid development of stable CHO cell lines for HIV vaccine production.

O'Rourke SM, Byrne G, Tatsuno G, Wright M, Yu B, Mesa KA, Doran RC, Alexander D, Berman PW.

PLoS One. 2018 Aug 2;13(8):e0197656. doi: 10.1371/journal.pone.0197656. eCollection 2018.

4.

Glycan modifications to the gp120 immunogens used in the RV144 vaccine trial improve binding to broadly neutralizing antibodies.

Doran RC, Tatsuno GP, O'Rourke SM, Yu B, Alexander DL, Mesa KA, Berman PW.

PLoS One. 2018 Apr 24;13(4):e0196370. doi: 10.1371/journal.pone.0196370. eCollection 2018.

5.

Characterization of a monoclonal antibody to a novel glycan-dependent epitope in the V1/V2 domain of the HIV-1 envelope protein, gp120.

Doran RC, Morales JF, To B, Morin TJ, Theolis R Jr, O'Rourke SM, Yu B, Mesa KA, Berman PW.

Mol Immunol. 2014 Nov;62(1):219-226. doi: 10.1016/j.molimm.2014.06.025. Epub 2014 Jul 11.

Supplemental Content

Loading ...
Support Center